Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Encorafenib
Related studies linked through entity extraction aliases.
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- Status
- TERMINATED
- Phase
- NA
PF-07284892 in Participants With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
- Status
- RECRUITING
- Phase
- N/A
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation
- Status
- TERMINATED
- Phase
- PHASE2
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
- Status
- RECRUITING
- Phase
- PHASE2
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
- Status
- TERMINATED
- Phase
- PHASE2
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
- Status
- RECRUITING
- Phase
- N/A
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
- Status
- TERMINATED
- Phase
- PHASE2
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
- Status
- TERMINATED
- Phase
- PHASE2